ubiquitin conjugating enzyme E2 D N-terminal like (pseudogene)Genealiases: []
Q-omics provides the consensus-scored UBE2DNL profile across patient tissues and cancer cell-line models. UBE2DNL expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, UBE2DNL is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, UBE2DNL RNA expression shows 7,818 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where UBE2DNL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2DNL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2DNL survival associations across molecular data types. UBE2DNL RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2DNL RNA expression–survival associations across cancer types. High UBE2DNL expression shows unfavorable associations in UVM, UCS, ACC, KICH, KIRC and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for UBE2DNL RNA expression.
This table summarizes UBE2DNL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2DNL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2DNL shows lower tumor expression in KIRC, THCA, CHOL and LIHC. The KIRC box plot shows higher UBE2DNL RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p < 0.001).
This table shows molecular features associated with UBE2DNL in patient tissues and cancer cell lines. In patient samples, UBE2DNL shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2DNL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
